<DOC>
	<DOCNO>NCT00728091</DOCNO>
	<brief_summary>The primary objective study assess efficacy satavaptan versus placebo participant dilutional hyponatremia due SIADH . Secondary objective assess safety satavaptan , maintenance effect , clinical benefit participant .</brief_summary>
	<brief_title>A Phase III Study Evaluating Efficacy Safety Satavaptan Versus Placebo Patients With Dilutional Hyponatremia</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Hyponatremia</mesh_term>
	<mesh_term>Inappropriate ADH Syndrome</mesh_term>
	<mesh_term>Satavaptan</mesh_term>
	<criteria>Participants symptomatic syndrome inappropriate antidiuretic hormone secretion ( SIADH ) chronic hyponatremia Presence clinical sign hypovolemia ( e.g . orthostatic decrease blood pressure increase pulse rate , dry mucus membrane , decrease skin turgor ) Presence clinical sign hypervolemia ( e.g . generalize edema , jugular venous extension ) Participants adrenocortical insufficiency Participants hypothyroidism Participants know cause transient SIADH Participants psychogenic polydipsia beer potomania Concomitant use thiazide diuretic study Presence uncontrolled diabetes fast blood glucose ≥200 mg/dL ( ≥11.09 mmol/L ) time screen Participants impaired hepatic function liver cirrhosis ( ChildPugh AC ) Pregnant breastfeed woman The information intend contain consideration relevant participant 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>aquaretic</keyword>
	<keyword>SIADH</keyword>
</DOC>